Name:Zhejiang Yongning Pharmaceutical Co., Ltd.

Category:Corporation/Limited Liability Company

Trade Category: Manufacturer

Legal Representative:Mr.Ye

Employees:Above 1000 People

Address:<aleck.jin@ynpharm.com>;Meihuajing Rd 4, Huangyan

Website:http://www.ynpharm.com

Product/Service:Antibiotics,Cardiovascular Drugs

Overview

Our history

Zhejiang Yongning Pharmaceutical Co., Ltd., whose predecessor is Zhejiang Yongning Pharmaceutical Factory (established in 1974), has a total of 1200 staff, including 180 technicians and 11 senior professionals. The company is a “National Key High-tech Enterprise of Torch Program”, combining pharmaceutical research and development with production and sales.

Our product

The company has six classes of products, i.e. chemical pharmaceutical intermediates, drug substances, chemical drug products, Traditional Chinese Medicine Injection (TCMI), Chinese patent medicines, health-care products. There are more than 100 products, seven of which are granted independent intellectual property.

The company is a pioneer manufacturing side-chain products of cephalosporins in China, and takes the lead to fill gaps in the domestic market.

Yearly capacity: 300 tons of sterile cephalosporins’ APIs & 100,000,000 vials of cephalosporins for injection.

Our quality system

Yongning Pharma has developed and maintained a robust quality system and win high reputation.

Yongning Pharma is the FIRST US FDA - approved manufacturer of sterile cephalosporins' APIs in China.

Most of our products have been granted Chinese GMP certificates and some of them have been approved by U.S. FDA, Japanese PMDA and South Korean KFDA. It is worth mentioning that U.S. FDA accepts our production line of sterile cephalosporin powder for injection as well as these of non-sterile and sterile cephalosporin drug substances (API).

Also, one of sterile cephalosporin APIs is approved as a USP reference standard by U.S. Pharmacopeial Convention.

Our R&D

There are over 130 persons in our R&D teams and a great part of them have more than 10-year experiences. Our R&D teams focus on the development of cephalosporins products and other new products like anti-tumor, anti-virus and cardiovascular drugs.

The company has applied for 28 patents including 6 foreign patents, 11 of which have been authorized including one U.S. Patent.

The company has also set up many research & development institutions in many colleges & universities of Beijing, Shanghai, Nanjing etc., and has been classified as “Provincial High-Tech Enterprise Research & Development Center”.

Safflower yellow for injection, which is developed by the company independently and listed in the National High Technology Research and Development Program of China (863 Program), has been awarded a certificate of “National Key & New Product" and the Second Class Award of Zhejiang Province Scientific and Technological Progress.

The company is the first enterprise that establishes a GAP-compliant safflower-planting base and the fingerprints of safflower; our brand “KANGBA” has been rated as a famous trade mark of Zhejiang Province; our Danle Cholagogue Capsules and Cholic Acid Antitussive Tablets are listed as one of “Protected Traditional Chinese Medicinal Products”.

Our honor

The company has been rated as:

“National Export Advanced Township Enterprises”;

“Best Pharmaceutical Corporate Social Responsibility Enterprises in 2010”;

“China's Enterprises with Most Investment Value (Unlisted)” in 2011 and 2012;

“Zhejiang Big Tax-payers”;

“Top 10 of Provincial Pharmaceutical Industry”;

“Exemplary Enterprises with Good Faith in Zhejiang Province”;

“Provincial Innovative Demonstration Enterprises”;

“Provincial Outstanding Private Enterprises”, etc.

Our commitment

As a forty-year enterprise, Yongning Pharma will always follow pharmaceutical industry development plan and emphasize the importance of technological investment and innovation while taking “Whole-hearted for health and quality first; striving for excellence and higher position” as quality policy. Yongning Pharma will improve its organizational structure, strengthen the performance management, establish modern enterprise system, and strive for being a listed enterprise earlier with a principle of “valuing management, refining operation, responsibility, co-development”.